No new drug: study tracks bleeding in hemophilia b patients on usual care
NCT ID NCT05568459
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This study follows 11 males with Hemophilia B who already receive regular factor IX therapy to prevent bleeding. Researchers will collect information on bleeding events, treatment use, and quality of life over at least 6 months. No experimental treatment is given; the goal is to better understand the disease for future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barts Health NHS Trust, Royal London Hospital
London, E1 1FR, United Kingdom
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20057, United States
-
Indiana Hemophilia and Thrombosis Center
Indianapolis, Indiana, 46260, United States
-
Klinikum der Johann Wolfgang Goethe-Universitaet Frankfurt
Frankfurt, 60590, Germany
-
McMaster University Medical Centre - Hamilton Health Sciences
Hamilton, Ontario, L8N 3Z5, Canada
-
Mcgill University Health Center (MUHC)
Montreal, Quebec, H4A 3J1, Canada
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Southampton General Hospital
Southampton, Hampshire, SO16 6YD, United Kingdom
-
St. Thomas' Hospital
London, SE1 7EH, United Kingdom
-
University Hospital Hamburg Eppendorf
Hamburg, 20246, Germany
-
University Hospital of Regensburg
Regensburg, Bavaria, 93053, Germany
-
University of Colorado Hemophilia and Thrombosis Center
Aurora, Colorado, 80045, United States
-
University of Florida
Gainesville, Florida, 32610, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
-
Yale HTC
New Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Gene Editing's lasting impact: a 10-Year safety watch
- Can a single gene shot free hemophilia b patients from regular infusions?
- Can a video call replace the clinic for hemophilia pain relief?
- Newborn screening study aims to catch rare diseases at birth
- Monthly shot could free kids with hemophilia from frequent infusions